Platelets & Plasma
Platelets
-
Cazenave J, Waller C, Mendel I et al. Clinical experience with pathogen inactivation of platelet components for transfusion support. Scharf RE (ed): Progress and Challenges in Transfusion Medicine, Hemostasis and Hemotherapy. Freiburg i.Br., Karger, 2008, pp 248-263.
> View abstract
-
Cazenave JP, Isola H, Waller C et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3 year period. Transfusion DOI: 10.1111.j.1537-2995.2010.02873.x
> View abstract
-
Osselaer JC, Cazenave JP, Waller C et al. An active hemovigilance program characterizing the safety profile of 7,437 platelet transfusions prepared with photochemical treatment. Vox Sang 2008: 94;(4):315-323.
> View abstract
-
Osselaer JC, Doyen C, Defoin L et al. Universal adoption of photochemical treatment of platelet components: impact on platelet and red cell component use. Transfusion 2009;49:7:1412-22.
> View abstract
-
Osselaer JC, Messe N, Hervig T et al. A prospective observational cohort safety study of 5,106 platelet transfusions using components prepared with photochemical treatment. Transfusion 2008;48(6):1061-71.
> View abstract
-
Rasongles P, Angelini-Tibert MF, Simon P et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de la Reunion. Transfusion 2009;49:6:1083-91.
> View abstract
-
Schlenke P, Hagenah W, Irsch J et al. Safety and Clinical Efficacy of Platelet Prepared Pathogen Inactivation in Routine Use for Thrombocytopenic Patients. Annals of Hematology 2011;(Dec);90(12):1457-1465.
> View abstract
Plasma
-
Cazenave JP, Waller C, Kientz D et al. An active hemovigilance program characterizing the safety profile of 7,483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010;50(6):1210-10.
> View abstract
|